Targeted degradation of BET proteins in triple-negative breast cancer

Triple-negative breast cancers (TNBC) remain clinically challenging with a lack of options for targeted therapy. In this study, we report the development of a second-generation BET bromodomain (BRD) inhibitor, BETd-246, which exhibits superior selectivity, potency and antitumor activity. In human TN...

Full beskrivning

Sparad:
Bibliografiska uppgifter
I publikationen:Cancer Res
Huvudupphovsmän: Bai, Longchuan, Zhou, Bing, Yang, Chao-Yie, Ji, Jiao, McEachern, Donna, Przybranowski, Sally, Jiang, Hui, Hu, Jiantao, Xu, Fuming, Zhao, Yujun, Liu, Liu, Fernandez-Salas, Ester, Xu, Jing, Dou, Yali, Wen, Bo, Sun, Duxin, Meagher, Jennifer, Stuckey, Jeanne, Hayes, Daniel F., Li, Shunqiang, Ellis, Matthew J., Wang, Shaomeng
Materialtyp: Artigo
Språk:Inglês
Publicerad: 2017
Ämnen:
Article
Länkar:https://ncbi.nlm.nih.gov/pmc/articles/PMC5413378/
https://ncbi.nlm.nih.gov/pubmed/28209615
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1158/0008-5472.CAN-16-2622
Taggar: Lägg till en tagg
Inga taggar, Lägg till första taggen!

Liknande verk